Registration Dossier

Administrative data

Description of key information

No data available.

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

No data available.

Justification for classification or non-classification

There is no repeated dose toxicity study with bromhydrin-valerate (CAS No.54605-02-6) available. However, due to its chemical structure bromhydrin-valerate belongs to the group of steroids characterised by an hydroxyl group on C11 and a carboxyl ester on C21 which is typical for glucocorticoids. Therefore, it is assumed that for glucocorticoids typical toxicological properties occur.

Following repeated exposure typical glucocorticoid effects (impaired wound healing, effects on calcium and phosphate metabolism, increased intra-ocular pressure after primarily local contamination, promotion of the spread of infection, degragation of lymphatic tissue, inhibition of the adrenal cortex, impairment of hematogenic tissue) are to be expected.

Based on animal experiments and human experience with glucocorticoids the following self classification of bromhydrin-valerate is recommended according to Regulation (EC) No. 1272/2008 (CLP):

STOT Rep. Exp. 1 (H372: Causes damage to organs through prolonged or repeated exposure).